BCR-ABL Quantitative with p210 Breakpoint near me in Coimbatore

The BCR-ABL gene is an abnormal fusion gene formed when parts of the BCR gene on chromosome 22 and the ABL gene on chromosome 9 join together, a change known as the Philadelphia chromosome. This fusion produces an abnormal protein that drives uncontrolled growth of white blood cells, which is a hallmark of Chronic Myeloid Leukemia (CML).

The BCR-ABL Quantitative with p210 Breakpoint test uses real-time PCR to detect and measure the p210 transcript in a blood sample. It can also identify major, minor, or micro translocations of the BCR-ABL gene, providing detailed information about the specific genetic changes in CML. This information is important for confirming diagnosis, guiding targeted therapy, and monitoring disease progression or response to treatment.

Doctors may recommend this test for individuals suspected to have Chronic Myeloid Leukemia (CML) or those experiencing symptoms such as fatigue, unexplained weight loss, fever, night sweats, or an enlarged spleen. It is also important for patients undergoing CML treatment to assess how well therapy is working, monitor disease progression, and guide targeted treatment decisions. The test helps diagnose CML, detect major, minor, or micro BCR-ABL translocations, and provide information on the p210 transcript, enabling doctors to plan and adjust treatment effectively.

It is important to provide a brief clinical history or doctor’s prescription at the time of sample collection to ensure accurate analysis.

Laboratory test results may vary depending on the testing method and platform used. Therefore, lab results should always be interpreted by a qualified hematologist or oncologist, as detection of BCR-ABL requires expert guidance to determine next steps in diagnosis, treatment, or follow-up monitoring. Patients should avoid self-diagnosis or treatment based on results alone.